Use: Labeled indications
- Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older.
- Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older.
- Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE CLARINEX is a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. (1.1) Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. (1.2) Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older.
(1.3) 1.1 Seasonal Allergic Rhinitis CLARINEX ® is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. 1.2 Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. 1.3 Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older.
Contraindications
4 CONTRAINDICATIONS CLARINEX Tablets, RediTabs, and Oral Solution are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)]. Hypersensitivity (4, 6.2)
US FDA labelDosing: Adult
Although the oral solution and the orally disintegrating tablet formulation of desloratadine may be available in the marketplace, CLARINEX ® Oral Solution and CLARINEX ® RediTabs ® Tablets are no longer marketed. CLARINEX Tablets, Oral Solution, or RediTabs Tablets may be taken without regard to meals. Place CLARINEX (desloratadine) RediTabs Tablets on the tongue and allow to disintegrate before swallowing.
Tablet disintegration occurs rapidly. Administer with or without water. Take tablet immediately after opening the blister. The age-appropriate dose of CLARINEX Oral Solution should be administered with a commercially available measuring dropper or syringe that is calibrated to deliver 2 mL and 2.5 mL (½ teaspoon). Dosage (by age): Adults and Adolescents 12 Years of Age and Over: CLARINEX Tablets - one 5 mg tablet once daily or CLARINEX RediTabs Tablets - one 5 mg tablet once daily or CLARINEX Oral Solution - 2 teaspoonfuls (5 mg in 10 mL) once daily (2) Children 6 to 11 Years of Age: CLARINEX Oral Solution - 1 teaspoonful (2.5 mg in 5 mL) once daily or CLARINEX RediTabs Tablets - one 2.5 mg tablet once daily (2) Children 12 Months to 5 Years of Age: CLARINEX Oral Solution - ½ teaspoonful (1.25 mg in 2.5 mL) once daily (2) Children 6 to 11 Months of Age: CLARINEX Oral Solution - 2 mL (1 mg) once daily (2)
2.1 Adults and Adolescents 12 Years of Age and Over
2.1 Adults and Adolescents 12 Years of Age and Over The recommended dose of CLARINEX Tablets or CLARINEX RediTabs Tablets is one 5-mg tablet once daily. The recommended dose of CLARINEX Oral Solution is 2 teaspoonfuls (5 mg in 10 mL) once daily.
2.2 Children 6 to 11 Years of Age
2.2 Children 6 to 11 Years of Age The recommended dose of CLARINEX Oral Solution is 1 teaspoonful (2.5 mg in 5 mL) once daily. The recommended dose of CLARINEX RediTabs Tablets is one 2.5-mg tablet once daily.
2.3 Children 12 Months to 5 Years of Age
2.3 Children 12 Months to 5 Years of Age The recommended dose of CLARINEX Oral Solution is ½ teaspoonful (1.25 mg in 2.5 mL) once daily.
2.4 Children 6 to 11 Months of Age
2.4 Children 6 to 11 Months of Age The recommended dose of CLARINEX Oral Solution is 2 mL (1 mg) once daily.
2.5 Adults with Hepatic or Renal Impairment
2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see Clinical Pharmacology (12.3)].
Dosing: Altered kidney function
2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see Clinical Pharmacology (12.3)].
8.6 Renal Impairment Dosage adjustment for patients with renal impairment is recommended [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment Dosage adjustment for patients with hepatic impairment is recommended [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].
2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The recommended dose of CLARINEX Oral Solution in the pediatric population is based on cross-study comparison of the plasma concentration of CLARINEX in adults and pediatric subjects. The safety of CLARINEX Oral Solution has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies.
Since the course of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria and the effects of CLARINEX are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients. The effectiveness of CLARINEX Oral Solution in these age groups is supported by evidence from adequate and well-controlled studies of CLARINEX Tablets in adults.
The safety and effectiveness of CLARINEX Tablets or CLARINEX Oral Solution have not been demonstrated in pediatric patients less than 6 months of age. [See Clinical Pharmacology (12.3).] The CLARINEX RediTabs 2.5-mg tablet has not been evaluated in pediatric patients. Bioequivalence of the CLARINEX RediTabs Tablet and the previously marketed RediTabs Tablet was established in adults.
In conjunction with the dose-finding studies in pediatrics described, the pharmacokinetic data for CLARINEX RediTabs supports the use of the 2.5-mg dose strength in pediatric patients 6 to 11 years of age.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. [See Clinical Pharmacology (12.3).]
Dosage forms
Philippines
- Film-coated tablet: 5 mg
- Syrup: 2.5 mg/5 mL
- Tablet: 5 mg
Registered products in the Philippines
31 products registered with the Food and Drug Administration (FDA) Philippines list Desloratadine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Desloratidine (1 product). Products registered under these spellings are included in the table and marked.
All registered products31
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AERIUSDesloratadine | 2.5 mg/5 mL SyrupPh. Eur Type III Amber glass bottle with a tamper-evident child-resistant polypropylene cap with laminated liner with polyethylene as the product contact surface and a polyethylene break ring x 60 mL (Box of 1’s) | Rx | Organon Heist bvBelgium | Importer: Organon (Philippines) Incorporated | DRP-8946 | Jul 8, 2031 | |
AeriusDesloratadine | 5 mg TabletPVC-PCTFE/Aluminum Foil x 10's (Box of 100's); PVC-PCTFE/Aluminum Foil x 2's (Box of 2's as Physician's Sample); PVC-PCTFE/Aluminum Foil x 10's (Box of 10's as Physician's Sample) | Rx | Organon Heist b.vBelgium | Importer: Organon (Philippines) Incorporated | DR-XY39221 | Mar 25, 2031 | |
AizeneDesloratadine | 2.5 mg/5 mL Syrup (Mixed Fruit Flavor)PET amber bottle with cap x 60 mL (Box of 1's) | Rx | Gracure Pharmaceuticals Ltd.India | Despina Pharma Inc. | DRP-15449 | Jul 12, 2029 | |
AlesydDesloratadine | 2.5 mg / 5mL SyrupUSP Type III Amber Glass Bottle with 20 mm foam-lined PP aluminum cap x 60 mL (Box of 1's) | Rx | Sydenham Laboratories, Inc.Philippines | — | DRP-12904 | Oct 27, 2027 | |
AllergonDesloratadine | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 6's (Box of 12's) | Rx | Hainan Poly Pharm. Co., Ltd.China | AMB HK Enterprises Inc. | DR-XY44123 | Feb 2, 2028 | |
AllergonDesloratadine | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 6's (Box of 12's) | Rx | Hainan Poly Pharm. Co., Ltd.China | FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc. | DRP-15225 | Feb 2, 2028 | |
AroledDesloratadine | 2.5 mg/5 mL Syrup (Orange Flavor)PET Bottle x 60 ml (Box of 1’s) | Rx | Stallion Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-3743-01 | May 14, 2032 | |
AroledDesloratadine | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | D & G PharmaImporter: Ambica International Corporation | DRP-4290-02 | Mar 8, 2028 | |
DeslodineDesloratadine | 2.5 mg/5 mL Syrup (Orange Flavor)60 mL PET Bottle (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation | DRP-3743 | May 14, 2032 | |
DeslodineDesloratadine | 5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation | DRP-4290-01 | Mar 8, 2028 | |
DeslogenDesloratadine | 2.5 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DR-XY42707 | Oct 2, 2028 | |
DeslogenDesloratadine | 2.5 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-15173 | Oct 2, 2028 | |
DeslogenDesloratadine | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7291 | Mar 12, 2031 | |
DeslorastalDesloratadine | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-4290 | Mar 8, 2028 | |
DeslotrisDesloratadine | 5 mg Film-Coated TabletAlu-Alu Blister Pack X 10's (Box of 30's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-18174 | May 21, 2031 | |
DestacureDesloratadine | 2.5 mg/5mL SyrupPET amber-colored bottle with white ROPP cap x 60 mL (Box of 1's) | Rx | Gracure Pharmaceutical Ltd.India | Aglobal Care, Inc. | DRP-15593 | Aug 7, 2029 | |
2.5mg/5ml SyrupAmber PET bottle x 60 mL (Box of 1's) | Rx | Gracure Pharmaceutical Ltd.India | Healol Pharma Corporation | DRP-16754 | Jul 11, 2030 | ||
DestavellDesloratadine | 5 mg Film-Coated TabletAluminum/EAA Foil Strip x 10's (Box of 30's) | Rx | PT. Novell Pharmaceutical LaboratoriesGunung Putri Bogor 16962 - Indonesia | Prosweal Healthcare Inc. | DR-XY47619 | Dec 21, 2031 | |
DezlotinDesloratadine | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's) | Rx | Aurochem Pharmaceuticals (India) Pvt., Ltd.India | Endure Medical, Inc. | DR-XY43831 | Oct 27, 2029 | |
DonzelpinDesloratadine | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-10787 | Nov 19, 2031 | |
Genodes-5Desloratadine | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Sydler Remedies Pvt. LimitedIndia | Medethix, Inc. | DRP-3757 | Oct 25, 2029 | |
Histalor-DDesloratadine | 5 mg Film-Coated TabletAlu/PVDC Film Blister Pack x 10 (Box of 100's) | Rx | Sai Mirra Innopharm Pvt. Ltd.India | Eon Pharmatek Inc. | DR-XY47540 | Nov 18, 2031 | |
KiddiesDesloratadine | 2.5 mg/5 mL SyrupAmber PET Bottle x 60 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-4707 | Sep 13, 2028 | |
Lora-DDesloratadine | 5 mg Film-Coated TabletPVC/Alu Blister Pack x 10's (Box of 30's) | Rx | Ind-Swift LimitedIndia | Ritemed Phils., Inc. | DR-XY42644 | Sep 17, 2036 | |
Lorahist 5Desloratadine | 5 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | Rx | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY49812 | Sep 29, 2031 | |
NoneDesloratadine | 5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4290-03 | Mar 8, 2028 | |
SedlorDesloratadine | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Medchem International, Inc.India | Pharma-Surrey International, Inc. | DRP-3343 | Nov 2, 2028 | |
Sylergy NeoDesloratadine | 2.5 mg / 5mL SyrupUSP Type III Amber Glass Bottle with 20 mm foam-lined PP aluminum cap x 60 mL (Box of 1's) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-12903 | Oct 27, 2027 | |
UnbrandedDesloratadine | 2.5 mg/5 mL Syrup (Orange Flavor)60 mL PET Bottle (Box of 1’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-3743-02 | May 14, 2032 | |
UnbrandedDesloratadine | 5 mg TabletAlu-Alu Blister Strip x 10's (Box of 100's) | Rx | UNILAB, Inc.Metro Manila | UNILAB, Inc. | DR-XY40082 | Sep 22, 2031 | |
ZudemDesloratadine | 5 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DRP-7775 | Sep 13, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS CLARINEX Tablets are supplied as: Light blue, film-coated tablets embossed with “C5” containing 5 mg desloratadine. Light blue, film-coated tablets embossed with an elongated letters “S” and “P” on one side and plain on the other, containing 5 mg desloratadine. CLARINEX Tablets - 5 mg (3)
Warnings/Precautions
Warnings and precautions (US label) US FDA label
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported. In such cases, stop CLARINEX at once and consider alternative treatments. (5.1) 5.1 Hypersensitivity Reactions Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported after administration of desloratadine. If such a reaction occurs, therapy with CLARINEX should be stopped and alternative treatment should be considered. [See Adverse Reactions (6.2).]
Drug interactions
7.1 Inhibitors of Cytochrome P450 3
7.1 Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]
7.2 Fluoxetine
7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]
7.3 Cimetidine
7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]
Adverse reactions
- The following adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity reactions. [See Warnings and Precautions (5.1).] The most common adverse reactions (reported in ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adults and Adolescents Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2834 patients ages 12 years or older received CLARINEX Tablets at doses of 2.5 mg to 20 mg daily, of whom 1655 patients received the recommended daily dose of 5 mg.
In patients receiving 5 mg daily, the rate of adverse events was similar between CLARINEX and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the CLARINEX group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving desloratadine.
All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of CLARINEX Tablets (5 mg once daily), and that were more common with CLARINEX Tablets than placebo, are listed in Table 1. Table 1: Incidence of Adverse Events Reported by ≥2% of Adult and Adolescent Allergic Rhinitis Patients Receiving CLARINEX Tablets Adverse Event CLARINEX Tablets 5 mg (n=1655) Placebo (n=1652) Infections and Infestations Pharyngitis 4.1% 2.0% Nervous System Disorders Somnolence 2.1% 1.8% Gastrointestinal Disorders Dry Mouth 3.0% 1.9% Musculoskeletal and Connective Tissue Disorders Myalgia 2.1% 1.8% Reproductive System and Breast Disorders Dysmenorrhea 2.1% 1.6% General Disorders and Administration Site Conditions Fatigue 2.1% 1.2% The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in CLARINEX and placebo-treated patients.
There were no differences in adverse events for subgroups of patients as defined by gender, age, or race. Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic idiopathic urticaria, 211 patients ages 12 years or older received CLARINEX Tablets and 205 received placebo. Adverse events that were reported by greater than or equal to 2% of patients who received CLARINEX Tablets and that were more common with CLARINEX than placebo were (rates for CLARINEX and placebo, respectively): headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%), pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).
Pediatrics Two hundred and forty-six pediatric subjects 6 months to 11 years of age received CLARINEX Oral Solution for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1.0 mg once a day.
In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects. In subjects 2 to 5 years of age, adverse events reported for CLARINEX and placebo in at least 2 percent of subjects receiving CLARINEX Oral Solution and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%) and varicella (3.6%, 0%).
In subjects 12 months to 23 months of age, adverse events reported for the CLARINEX product and placebo in at least 2 percent of subjects receiving CLARINEX Oral Solution and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%). In subjects 6 months to 11 months of age, adverse events reported for CLARINEX and placebo in at least 2 percent of subjects receiving CLARINEX Oral Solution and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3.0%, 1.6%), and nausea (3.0%, 0%).
There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pediatric subjects receiving CLARINEX Oral Solution in the clinical trials discontinued treatment because of an adverse event.
6.2 Post-Marketing Experience
6.2 Post-Marketing Experience Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following spontaneous adverse events have been reported during the marketing of desloratadine: Cardiac disorders: tachycardia, palpitations Respiratory, thoracic and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: rash, pruritus Nervous system disorders: psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures (reported in patients with and without a known seizure disorder) Immune system disorders: hypersensitivity reactions (such as urticaria, edema and anaphylaxis) Investigations: elevated liver enzymes including bilirubin Hepatobiliary disorders: hepatitis Metabolism and nutrition disorders: increased appetite
Adverse reaction frequency tables (US label) US FDA label
| Adverse Event | CLARINEX Tablets 5 mg (n=1655) | Placebo (n=1652) |
|---|---|---|
| Infections and Infestations | ||
| Pharyngitis | 4.1% | 2.0% |
| Nervous System Disorders | ||
| Somnolence | 2.1% | 1.8% |
| Gastrointestinal Disorders | ||
| Dry Mouth | 3.0% | 1.9% |
| Musculoskeletal and Connective Tissue Disorders | ||
| Myalgia | 2.1% | 1.8% |
| Reproductive System and Breast Disorders | ||
| Dysmenorrhea | 2.1% | 1.6% |
| General Disorders and Administration Site Conditions | ||
| Fatigue | 2.1% | 1.2% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary The limited available data with CLARINEX in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are no adequate and well-controlled studies in pregnant women. Desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (AUC)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (RHD) of 5 mg/day.
Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at the AUC-based exposures of desloratadine approximately 230 times that at the RHD. Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F 1 pups at the summed AUC-based exposures of desloratadine and its metabolite approximately 70 times or greater than that at the RHD [see Data].
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Desloratadine was given orally during organogenesis to pregnant rats at doses of 6, 24 and 48 mg/kg/day (approximately 50, 200 and 320 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
No fetal malformations were present. Reduced fetal weights and skeletal variations noted at doses of 24 and 48 mg/kg/day were likely secondary to the maternal toxicities of reduced body weight gain and food consumption observed at the same doses. Desloratadine was also given orally during organogenesis to pregnant rabbits at doses of 15, 30 and 60 mg/kg/day (approximately 30, 70 and 230 times the AUC-based exposure of desloratadine at the RHD).
No adverse effects to the fetus were noted. Reduced maternal body weight gain was noted in rabbits at 60 mg/kg/day. In a peri- and post-natal development study, desloratadine was given to rats orally during the peri-natal (Gestation Day 6) through lactation periods (Postpartum Day 21) at doses of 3, 9 and 18 mg/kg/day. Reduced body weight and slow righting reflex were reported in F 1 pups at doses of 9 mg/kg/day or greater (approximately 70 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD).
Desloratadine had no effect on F 1 pup development at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Maternal toxicities including reduced body weight gain and food consumption were noted at 18 mg/kg/day for F 0 dams. F 1 offspring were subsequently mated and there was no developmental toxicity for F 2 pups observed.
Mechanism of action
12.1 Mechanism of Action Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2–3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited histamine release from human mast cells in vitro.
Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Wheal and Flare: Human histamine skin wheal studies following single and repeated 5-mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5-mg group over the 28-day treatment period.
The clinical relevance of histamine wheal skin testing is unknown. Effects on QT c: Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In CLARINEX-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo.
The QT interval was corrected for heart rate (QT c) by both the Bazett and Fridericia methods. Using the QT c (Bazett) there was a mean increase of 8.1 msec in CLARINEX-treated subjects relative to placebo. Using QT c (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated subjects relative to placebo. No clinically relevant adverse events were reported.
Pharmacokinetics
In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
Elimination The mean plasma elimination half-life of desloratadine was approximately 27 hours.
The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency.
Analysis of plasma 3-hydroxydesloratadine showed similar T max and half-life values compared to desloratadine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5-mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively. Neither food nor grapefruit juice had an effect on the bioavailability (C max and AUC) of desloratadine.
The pharmacokinetic profile of CLARINEX Oral Solution was evaluated in a three-way crossover study in 30 adult volunteers. A single dose of 10 mL of CLARINEX Oral Solution containing 5 mg of desloratadine was bioequivalent to a single dose of 5-mg CLARINEX Tablet. Food had no effect on the bioavailability (AUC and C max) of CLARINEX Oral Solution.
The pharmacokinetic profile of CLARINEX RediTabs Tablets was evaluated in a three-way crossover study in 24 adult volunteers. A single CLARINEX RediTabs Tablet containing 5 mg of desloratadine was bioequivalent to a single 5-mg CLARINEX RediTabs Tablet (original formulation) for both desloratadine and 3-hydroxydesloratadine.
Food and water had no effect on the bioavailability (AUC and C max) of CLARINEX RediTabs Tablets. Distribution Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function.
Metabolism Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine.
In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years.
There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1,462) and Hispanics (2%, n=1,063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers.
Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with CLARINEX Oral Solution for 15–35 days.
In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out. Elimination The mean plasma elimination half-life of desloratadine was approximately 27 hours.
C max and AUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14 C-desloratadine dose, which was equally distributed in urine and feces as metabolic products.
Analysis of plasma 3-hydroxydesloratadine showed similar T max and half-life values compared to desloratadine.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Clarinex · Organon LLC [US FDA-approved label, version 6, May 17, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c671342e-69a2-4ca5-abc2-8166ed4240d4
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .